| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2005, Vol. 106, No. 12, pp. 3811-3815. Prepublished online as a Blood First Edition Paper on August 4, 2005; DOI 10.1182/blood-2005-06-2495.
Submitted June 23, 2005
Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA * Corresponding author; email: dws{at}email.unc.edu.
Previously we reported that we could increase the fraction of carboxylated factor X by reducing the affinity of the propeptide for its binding site on human gamma glutamyl carboxylase. We attributed this to an increased turnover rate. However, even with the reduced affinity propeptide, when sufficient over-production of factor X is achieved, there is still a significant fraction of uncarboxylated recombinant factor X. We report here that the factor X of such a cell line was only 52% carboxylated but that the fraction of carboxylated factor X could be increased to 92% by co-expressing the recently identified gene for vitamin K epoxide reductase. Because vitamin K is in excess in both the un-transfected and VKOR transfected cells, the simplest explanation for this result is that vitamin K epoxide reductase catalyzes both the reduction of vitamin K epoxide to vitamin K and the conversion of vitamin K to vitamin K hydroquinone. In addition to its mechanistic relevance, this observation has practical implications for over-producing recombinant vitamin K dependent proteins for therapeutic use.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||